The document provides information about the 19th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) conference that will take place from December 2-4, 2021 in Los Angeles. The conference will explore new frontiers in metabolism and link basic research to clinical practice. It will cover topics such as obesity, diabetes, cardiovascular disease, kidney disease, and liver disease. The conference aims to bring together researchers, physicians, and healthcare professionals to collaborate and discuss the latest scientific and clinical developments in metabolic diseases. It will feature distinguished global faculty, oral and poster presentations, and opportunities for in-person and virtual attendance.
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Man...Chi Pham
Slides | 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
Date: January 28, 2019
The document discusses pharmacokinetics of drugs in critically ill patients. It notes that dosages are usually determined from healthy volunteers but critically ill patients have increased cardiac output, leaky capillaries, organ dysfunction and other factors that impact drug distribution and clearance. This can result in low drug concentrations. The document recommends increasing loading doses to account for higher volumes of distribution, increasing dosage frequency to compensate for higher clearances, and being aware of changes to protein binding. It also notes the impact of renal replacement therapy and importance of therapeutic drug monitoring to optimize dosing for critically ill patients.
Monitoring Plan and Basic Monitoring Visits: Everything that a CRA Needs to KnowTrialJoin
This document provides an overview of the key components of a clinical trial monitoring plan and basic monitoring visits that a clinical research associate (CRA) needs to be aware of. It discusses the main parts of a monitoring plan including CRA site assignments, guidelines, visit timelines, and types of visits. It also explains the differences between traditional and risk-based monitoring approaches. Finally, it outlines the basic monitoring visits that occur, including site selection, initiation, regular monitoring, and close-out visits. The document is intended to educate both new and experienced CRAs on monitoring best practices.
Explaining the Different Types of Routine Monitoring VisitsAnand Butani
In the clinical research industry, there are several types of basic monitoring visits that everyone involved in it should differentiate, especially CRAs (monitors). A CRA (clinical research associate) or a monitor is the person responsible for visiting a site in order to ensure that the clinical trial is being conducted properly. The CRA’s tasks include on-site visits and ensuring compliance, subjects’ safety, data quality and integrity, etc. Although clinical trials belong in the medical field, a CRA doesn’t have to be a doctor or a medical professional. It’s enough if a CRA has a background in Life Sciences, past experience in clinical trials (most often as a coordinator), and the proper training.
The main monitoring visits are the Site Selection Visit, Site Initiation Visit, Regular (Interim) Monitoring Visits, Site Close-Out Visit, and the Pre-Audit Visit. Out of all these monitoring visits, here we’ll pay more attention to the Routine Monitoring Visits, as one of the most frequent and important visits at a site.
This document provides an overview of Novartis' Q3 2021 results investor presentation. It includes sections on company overview, financial performance, key growth drivers, and an announcement to commence a strategic review of the Sandoz division to maximize shareholder value. The strategic review will explore options ranging from retaining Sandoz to a potential separation, and an update will be provided by the end of 2022.
Tirzepatide versus Semiglutide Once Weekly in Patients with Type 2 Diabetes.pdfHaramaya University
This randomized controlled trial compared the efficacy and safety of three doses of tirzepatide (5 mg, 10 mg, and 15 mg), a dual GLP-1 and GIP receptor agonist, to semaglutide (1 mg), a GLP-1 receptor agonist, in 1879 patients with type 2 diabetes inadequately controlled with metformin alone. The primary outcome was the change in HbA1c from baseline to 40 weeks. Key secondary outcomes included changes in body weight and achievement of HbA1c targets. Tirzepatide at all doses resulted in greater reductions in HbA1c and body weight compared to semaglutide and was found to be noninferior and
DAPT involves using aspirin along with another antiplatelet drug such as clopidogrel, prasugrel, or ticagrelor. It is indicated after PCI to prevent stent thrombosis. The risks of DAPT include bleeding complications. The duration of DAPT depends on factors like the underlying condition, stent type, and generation of DES. For patients who cannot take oral anticoagulants for atrial fibrillation, aspirin alone is recommended, but clopidogrel plus aspirin may also be reasonable. Routine platelet function or genetic testing is not recommended to guide P2Y12 inhibitor therapy.
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Man...Chi Pham
Slides | 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
Date: January 28, 2019
The document discusses pharmacokinetics of drugs in critically ill patients. It notes that dosages are usually determined from healthy volunteers but critically ill patients have increased cardiac output, leaky capillaries, organ dysfunction and other factors that impact drug distribution and clearance. This can result in low drug concentrations. The document recommends increasing loading doses to account for higher volumes of distribution, increasing dosage frequency to compensate for higher clearances, and being aware of changes to protein binding. It also notes the impact of renal replacement therapy and importance of therapeutic drug monitoring to optimize dosing for critically ill patients.
Monitoring Plan and Basic Monitoring Visits: Everything that a CRA Needs to KnowTrialJoin
This document provides an overview of the key components of a clinical trial monitoring plan and basic monitoring visits that a clinical research associate (CRA) needs to be aware of. It discusses the main parts of a monitoring plan including CRA site assignments, guidelines, visit timelines, and types of visits. It also explains the differences between traditional and risk-based monitoring approaches. Finally, it outlines the basic monitoring visits that occur, including site selection, initiation, regular monitoring, and close-out visits. The document is intended to educate both new and experienced CRAs on monitoring best practices.
Explaining the Different Types of Routine Monitoring VisitsAnand Butani
In the clinical research industry, there are several types of basic monitoring visits that everyone involved in it should differentiate, especially CRAs (monitors). A CRA (clinical research associate) or a monitor is the person responsible for visiting a site in order to ensure that the clinical trial is being conducted properly. The CRA’s tasks include on-site visits and ensuring compliance, subjects’ safety, data quality and integrity, etc. Although clinical trials belong in the medical field, a CRA doesn’t have to be a doctor or a medical professional. It’s enough if a CRA has a background in Life Sciences, past experience in clinical trials (most often as a coordinator), and the proper training.
The main monitoring visits are the Site Selection Visit, Site Initiation Visit, Regular (Interim) Monitoring Visits, Site Close-Out Visit, and the Pre-Audit Visit. Out of all these monitoring visits, here we’ll pay more attention to the Routine Monitoring Visits, as one of the most frequent and important visits at a site.
This document provides an overview of Novartis' Q3 2021 results investor presentation. It includes sections on company overview, financial performance, key growth drivers, and an announcement to commence a strategic review of the Sandoz division to maximize shareholder value. The strategic review will explore options ranging from retaining Sandoz to a potential separation, and an update will be provided by the end of 2022.
Tirzepatide versus Semiglutide Once Weekly in Patients with Type 2 Diabetes.pdfHaramaya University
This randomized controlled trial compared the efficacy and safety of three doses of tirzepatide (5 mg, 10 mg, and 15 mg), a dual GLP-1 and GIP receptor agonist, to semaglutide (1 mg), a GLP-1 receptor agonist, in 1879 patients with type 2 diabetes inadequately controlled with metformin alone. The primary outcome was the change in HbA1c from baseline to 40 weeks. Key secondary outcomes included changes in body weight and achievement of HbA1c targets. Tirzepatide at all doses resulted in greater reductions in HbA1c and body weight compared to semaglutide and was found to be noninferior and
DAPT involves using aspirin along with another antiplatelet drug such as clopidogrel, prasugrel, or ticagrelor. It is indicated after PCI to prevent stent thrombosis. The risks of DAPT include bleeding complications. The duration of DAPT depends on factors like the underlying condition, stent type, and generation of DES. For patients who cannot take oral anticoagulants for atrial fibrillation, aspirin alone is recommended, but clopidogrel plus aspirin may also be reasonable. Routine platelet function or genetic testing is not recommended to guide P2Y12 inhibitor therapy.
The document discusses the importance of reading, listening to, understanding, and obeying God's word as revealed in the Bible. It summarizes a story from the book of Nehemiah where Ezra and other religious leaders read from the Book of the Law to the people of Israel, explaining its meaning so that the people could understand. The people wept as they listened, realizing how their sins violated God's commands. However, their understanding of God's word also brought them fellowship and joy as they sought to obey what they had learned. The document emphasizes that Scripture has power to transform lives when read, heard, and followed.
The document discusses different classes of antibiotics, including penicillins, cephalosporins, carbapenems, macrolides, lincosamides, aminoglycosides, tetracyclines, fluoroquinolones, rifampin, metronidazole, and trimethoprim-sulfamethoxazole. It describes their mechanisms of action, spectrums of coverage, indications for use, and potential disadvantages or side effects. The document is authored by a 4th year medical student as part of a study on antibiotic classifications and properties.
Monitoring and auditing in clinical trialsJyotsna Kapoor
Monitoring and auditing are important quality control activities in clinical trials. Monitoring ensures accurate and compliant conduct of trials, while auditing independently evaluates trial conduct and compliance. Key aspects include:
Monitoring involves overseeing trial progress to ensure compliance. Monitors verify participant rights and data accuracy. Auditing independently examines trials and documents to determine GCP compliance. Audit findings help ensure future compliance. Together, monitoring and auditing protect participants and validate trial results.
The document discusses the Caravaggio Study, which evaluated the use of apixaban for treating venous thromboembolism in patients with cancer. The study excluded patients younger than 18, with an ECOG performance status of 3 or 4, a life expectancy under 6 months, recent use of anticoagulant therapy for over 72 hours, indications for anticoagulation other than VTE, certain drug interactions, antiplatelet therapy, active bleeding or high bleeding risk, or low hemoglobin, platelet count or kidney function. The study was led by Dr. Giancarlo Agnelli and published in the New England Journal of Medicine.
This document provides guidelines for classifying and diagnosing different types of diabetes. It discusses five general categories: type 1 diabetes, type 2 diabetes, specific types due to other causes like monogenic diabetes, gestational diabetes mellitus, and diabetes related to other conditions like cystic fibrosis or organ transplantation. For each type, it provides recommendations for screening and diagnosis, including which tests to use and at what age or time periods patients should be tested. The guidelines are meant to help ensure accurate diagnosis and avoid missed or misdiagnoses.
Presented at PhUSE 2013
The evaluation of efficacy in oncology studies, in particular for solid tumors, is pretty standard and well defined by several regulatory guidance (e.g. EMA and FDA), including some specific cancer type guidance (e.g. NSCLC from FDA).
Although some references will be also given for non-solid tumors, the paper will mainly focus on solid tumors efficacy
endpoints.
Overall Survival, Best Overall Response as per RECIST criteria, Progression Free Survival (PFS), Time to Progression (TTP), Best Overall Response Rate are some of the key efficacy indicators that will be discussed.
The document discusses key aspects of clinical trial strategy and design. It covers the different phases of clinical trials (Phase I, II, III) and provides guidance on optimizing trials at each phase. Phase I focuses on safety and dosing, Phase II evaluates efficacy and further safety, and Phase III confirms efficacy in a larger patient population. The document emphasizes establishing a detailed clinical development plan with timelines and costs to help guide development decisions and reduce risks.
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/h3HRvWGUj5A
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
1. A Case report of Heart Failure
2. Discussion on Heart Failure
3. Role of Peptides in Heart Failure
4. Importance of 30 days in heart failure
5. Role of ENTRESTO in Stable Heart Failure patient (PARADIGM-HF study)(HFrEF)
6. Biomarkers in Heart Failure
7. Role of ARNI in Hospitalized Heart Failure patient (PIONEER-HF study)
8. Role of ARNI in HFpEF (PARAMOUNT Trial)
9. Safety and usefulness of ACEI/ARB/ARNI
10. Role of SGPL2 inhibitors in HF with/without DM
Well-trained clinical research professionals are in high demand. The tremendous increase in medical technology and information in the last decade has resulted in an explosion of potential new drugs, devices and biologics that must be tested before being released for use by the public. The profession is constantly challenged to improve and streamline the clinical research programs in order to shorten the development timelines and control the cost for new product development
The Banff Classification of kidney transplant pathology began in 1991 to standardize the interpretation of transplant biopsies. It has since evolved and expanded to other organ transplants through biennial meetings. The classification uses lesion scoring and diagnostic categories but faces challenges in applying expensive new techniques like immunostaining in developing countries. Efforts are needed to share pathology resources and training to make the standards accessible worldwide.
The document provides information about opportunities in the clinical research industry. It discusses what clinical research is and the drug development process. It outlines the growing industry opportunity, with increasing demand for clinical research professionals and rapid investment growth in the field. Various career opportunities and paths in clinical research are also presented, along with salary ranges and eligibility requirements to work in clinical research.
This document outlines various clinical research activities and provides descriptions for each. It includes activities such as drug accountability, patient care, obtaining informed consent, patient education, scheduling, data management including query resolution, research chart management, case report form completion, safety reporting, screening and enrollment log management, source document development, subject registration, protocol training, meetings, and general protocol review.
SAE REPORTING TIMELINE AND COMPENSATION 2019Shweta Lal
This presentation is based on New Drug and Clinical Trial Rule 2019 which was published in 19 march 2019. I have described chapter VI ( compensation) and Seventh Schedule including SAE reporting timeline in India.
Regulatory documents in clinical researchDan Sfera
The document outlines various regulatory documents that must be maintained at clinical research sites, including an investigator's agreement signed by the principal investigator taking responsibility for the study conduct, financial disclosure forms for study staff, protocol signature pages signed by the PI and staff training logs to document that all personnel are qualified to perform assigned tasks. Other required documents include IRB approvals, subject enrollment logs, investigational product accountability records, safety reports, correspondence between the site and sponsor/IRB, a CLIA waiver if biological samples are collected, and an investigator's brochure containing information on the study drug.
- The EMPHASIS-HF trial studied the effects of adding eplerenone versus placebo to evidence-based heart failure therapy in 2737 patients with systolic heart failure and mild symptoms.
- Patients taking eplerenone experienced a 37% reduced risk of the primary composite endpoint of cardiovascular death or heart failure hospitalization compared to placebo.
- Eplerenone treatment was also associated with reduced risk of all-cause mortality compared to placebo.
- The trial was stopped early based on a recommendation from the data safety monitoring board due to clear benefits of eplerenone beyond prespecified stopping boundaries.
1) The patient has a 10.8% 10-year ASCVD risk, placing him in the intermediate risk category.
2) For patients in this category, guidelines recommend evaluating additional risk enhancers such as family history of premature CVD, metabolic syndrome, inflammation, and coronary artery calcium score.
3) Based on the assessment of risk enhancers, the guidelines recommend either moderate or high-intensity statin therapy.
This document provides guidance and answers frequently asked questions about completing Form FDA 1572, also known as the Statement of Investigator. The form is an agreement between the investigator and sponsor that provides information about the investigator's qualifications and research site, and commits the investigator to comply with FDA regulations for clinical investigations. Key points covered include when the form must be signed, qualifications of investigators, updating the form, use for foreign studies, and submitting the form to FDA. The guidance aims to help sponsors, investigators and others properly complete the 1572.
This document provides definitions for key terms related to clinical trials and good clinical practice. It defines 58 terms, including adverse event, protocol, investigator, informed consent, monitoring, quality assurance and quality control. The definitions aim to clarify the proper conduct of clinical research and protection of trial subjects, according to international ethical and regulatory standards.
BMJ Best Practice and BMJ Clinical Evidence are point-of-care decision support tools that combine the latest research evidence, guidelines, and expert opinion on prevention, diagnosis, treatment, and prognosis. They can be accessed through the La Trobe University Library databases. Users can browse topics or search for terms to find condition management information. Search results are organized by content type and relevance. Accounts can be created to save searches, bookmark pages, and access the resources mobilely. Help is available through various library guides and chat.
This document provides an introduction to and overview of the 12 recommendations from the Institute of Medicine on promoting global cardiovascular health. It discusses the global cardiovascular disease epidemic and some of the challenges in addressing it, including lack of awareness, competing priorities, and weak health systems. It then groups the 12 recommendations into three categories: building priorities, advocacy and funding; policy and program implementation; and data management, research and global coordination/reporting. For each recommendation, it provides a brief overview of the topic and highlights one or two related articles in the document. The introduction sets the stage for the in-depth discussion of each recommendation that follows in the subsequent articles.
This document provides guidelines for managing type 2 diabetes in older adults aged 70 and over. It was created by an international group of diabetes experts to address the special issues related to providing high-quality diabetes care for older populations. The guidelines aim to individualize care based on a person's functional status and medical comorbidities. It provides recommendations in areas like cardiovascular risk, education, renal impairment, and end-of-life care. The guidelines also emphasize the importance of comprehensive geriatric assessments and involving informal caregivers in diabetes management for older adults.
The document discusses the importance of reading, listening to, understanding, and obeying God's word as revealed in the Bible. It summarizes a story from the book of Nehemiah where Ezra and other religious leaders read from the Book of the Law to the people of Israel, explaining its meaning so that the people could understand. The people wept as they listened, realizing how their sins violated God's commands. However, their understanding of God's word also brought them fellowship and joy as they sought to obey what they had learned. The document emphasizes that Scripture has power to transform lives when read, heard, and followed.
The document discusses different classes of antibiotics, including penicillins, cephalosporins, carbapenems, macrolides, lincosamides, aminoglycosides, tetracyclines, fluoroquinolones, rifampin, metronidazole, and trimethoprim-sulfamethoxazole. It describes their mechanisms of action, spectrums of coverage, indications for use, and potential disadvantages or side effects. The document is authored by a 4th year medical student as part of a study on antibiotic classifications and properties.
Monitoring and auditing in clinical trialsJyotsna Kapoor
Monitoring and auditing are important quality control activities in clinical trials. Monitoring ensures accurate and compliant conduct of trials, while auditing independently evaluates trial conduct and compliance. Key aspects include:
Monitoring involves overseeing trial progress to ensure compliance. Monitors verify participant rights and data accuracy. Auditing independently examines trials and documents to determine GCP compliance. Audit findings help ensure future compliance. Together, monitoring and auditing protect participants and validate trial results.
The document discusses the Caravaggio Study, which evaluated the use of apixaban for treating venous thromboembolism in patients with cancer. The study excluded patients younger than 18, with an ECOG performance status of 3 or 4, a life expectancy under 6 months, recent use of anticoagulant therapy for over 72 hours, indications for anticoagulation other than VTE, certain drug interactions, antiplatelet therapy, active bleeding or high bleeding risk, or low hemoglobin, platelet count or kidney function. The study was led by Dr. Giancarlo Agnelli and published in the New England Journal of Medicine.
This document provides guidelines for classifying and diagnosing different types of diabetes. It discusses five general categories: type 1 diabetes, type 2 diabetes, specific types due to other causes like monogenic diabetes, gestational diabetes mellitus, and diabetes related to other conditions like cystic fibrosis or organ transplantation. For each type, it provides recommendations for screening and diagnosis, including which tests to use and at what age or time periods patients should be tested. The guidelines are meant to help ensure accurate diagnosis and avoid missed or misdiagnoses.
Presented at PhUSE 2013
The evaluation of efficacy in oncology studies, in particular for solid tumors, is pretty standard and well defined by several regulatory guidance (e.g. EMA and FDA), including some specific cancer type guidance (e.g. NSCLC from FDA).
Although some references will be also given for non-solid tumors, the paper will mainly focus on solid tumors efficacy
endpoints.
Overall Survival, Best Overall Response as per RECIST criteria, Progression Free Survival (PFS), Time to Progression (TTP), Best Overall Response Rate are some of the key efficacy indicators that will be discussed.
The document discusses key aspects of clinical trial strategy and design. It covers the different phases of clinical trials (Phase I, II, III) and provides guidance on optimizing trials at each phase. Phase I focuses on safety and dosing, Phase II evaluates efficacy and further safety, and Phase III confirms efficacy in a larger patient population. The document emphasizes establishing a detailed clinical development plan with timelines and costs to help guide development decisions and reduce risks.
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/h3HRvWGUj5A
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
1. A Case report of Heart Failure
2. Discussion on Heart Failure
3. Role of Peptides in Heart Failure
4. Importance of 30 days in heart failure
5. Role of ENTRESTO in Stable Heart Failure patient (PARADIGM-HF study)(HFrEF)
6. Biomarkers in Heart Failure
7. Role of ARNI in Hospitalized Heart Failure patient (PIONEER-HF study)
8. Role of ARNI in HFpEF (PARAMOUNT Trial)
9. Safety and usefulness of ACEI/ARB/ARNI
10. Role of SGPL2 inhibitors in HF with/without DM
Well-trained clinical research professionals are in high demand. The tremendous increase in medical technology and information in the last decade has resulted in an explosion of potential new drugs, devices and biologics that must be tested before being released for use by the public. The profession is constantly challenged to improve and streamline the clinical research programs in order to shorten the development timelines and control the cost for new product development
The Banff Classification of kidney transplant pathology began in 1991 to standardize the interpretation of transplant biopsies. It has since evolved and expanded to other organ transplants through biennial meetings. The classification uses lesion scoring and diagnostic categories but faces challenges in applying expensive new techniques like immunostaining in developing countries. Efforts are needed to share pathology resources and training to make the standards accessible worldwide.
The document provides information about opportunities in the clinical research industry. It discusses what clinical research is and the drug development process. It outlines the growing industry opportunity, with increasing demand for clinical research professionals and rapid investment growth in the field. Various career opportunities and paths in clinical research are also presented, along with salary ranges and eligibility requirements to work in clinical research.
This document outlines various clinical research activities and provides descriptions for each. It includes activities such as drug accountability, patient care, obtaining informed consent, patient education, scheduling, data management including query resolution, research chart management, case report form completion, safety reporting, screening and enrollment log management, source document development, subject registration, protocol training, meetings, and general protocol review.
SAE REPORTING TIMELINE AND COMPENSATION 2019Shweta Lal
This presentation is based on New Drug and Clinical Trial Rule 2019 which was published in 19 march 2019. I have described chapter VI ( compensation) and Seventh Schedule including SAE reporting timeline in India.
Regulatory documents in clinical researchDan Sfera
The document outlines various regulatory documents that must be maintained at clinical research sites, including an investigator's agreement signed by the principal investigator taking responsibility for the study conduct, financial disclosure forms for study staff, protocol signature pages signed by the PI and staff training logs to document that all personnel are qualified to perform assigned tasks. Other required documents include IRB approvals, subject enrollment logs, investigational product accountability records, safety reports, correspondence between the site and sponsor/IRB, a CLIA waiver if biological samples are collected, and an investigator's brochure containing information on the study drug.
- The EMPHASIS-HF trial studied the effects of adding eplerenone versus placebo to evidence-based heart failure therapy in 2737 patients with systolic heart failure and mild symptoms.
- Patients taking eplerenone experienced a 37% reduced risk of the primary composite endpoint of cardiovascular death or heart failure hospitalization compared to placebo.
- Eplerenone treatment was also associated with reduced risk of all-cause mortality compared to placebo.
- The trial was stopped early based on a recommendation from the data safety monitoring board due to clear benefits of eplerenone beyond prespecified stopping boundaries.
1) The patient has a 10.8% 10-year ASCVD risk, placing him in the intermediate risk category.
2) For patients in this category, guidelines recommend evaluating additional risk enhancers such as family history of premature CVD, metabolic syndrome, inflammation, and coronary artery calcium score.
3) Based on the assessment of risk enhancers, the guidelines recommend either moderate or high-intensity statin therapy.
This document provides guidance and answers frequently asked questions about completing Form FDA 1572, also known as the Statement of Investigator. The form is an agreement between the investigator and sponsor that provides information about the investigator's qualifications and research site, and commits the investigator to comply with FDA regulations for clinical investigations. Key points covered include when the form must be signed, qualifications of investigators, updating the form, use for foreign studies, and submitting the form to FDA. The guidance aims to help sponsors, investigators and others properly complete the 1572.
This document provides definitions for key terms related to clinical trials and good clinical practice. It defines 58 terms, including adverse event, protocol, investigator, informed consent, monitoring, quality assurance and quality control. The definitions aim to clarify the proper conduct of clinical research and protection of trial subjects, according to international ethical and regulatory standards.
BMJ Best Practice and BMJ Clinical Evidence are point-of-care decision support tools that combine the latest research evidence, guidelines, and expert opinion on prevention, diagnosis, treatment, and prognosis. They can be accessed through the La Trobe University Library databases. Users can browse topics or search for terms to find condition management information. Search results are organized by content type and relevance. Accounts can be created to save searches, bookmark pages, and access the resources mobilely. Help is available through various library guides and chat.
This document provides an introduction to and overview of the 12 recommendations from the Institute of Medicine on promoting global cardiovascular health. It discusses the global cardiovascular disease epidemic and some of the challenges in addressing it, including lack of awareness, competing priorities, and weak health systems. It then groups the 12 recommendations into three categories: building priorities, advocacy and funding; policy and program implementation; and data management, research and global coordination/reporting. For each recommendation, it provides a brief overview of the topic and highlights one or two related articles in the document. The introduction sets the stage for the in-depth discussion of each recommendation that follows in the subsequent articles.
This document provides guidelines for managing type 2 diabetes in older adults aged 70 and over. It was created by an international group of diabetes experts to address the special issues related to providing high-quality diabetes care for older populations. The guidelines aim to individualize care based on a person's functional status and medical comorbidities. It provides recommendations in areas like cardiovascular risk, education, renal impairment, and end-of-life care. The guidelines also emphasize the importance of comprehensive geriatric assessments and involving informal caregivers in diabetes management for older adults.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
This document provides a commentary from the National Kidney Foundation–Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD. The commentary work group agreed with most recommendations in the KDIGO guideline, including retaining the definition of CKD and incorporating albuminuria stages into CKD classification. However, some concerns were raised about including cause of disease in CKD staging and issues with GFR estimation and measuring albuminuria in practice. The commentary aims to help US practitioners interpret and apply the KDIGO guideline recommendations.
2014 Report: Medicines in Development for Older AmericansPhRMA
As life expectancy continues to climb—up to more than 81 years for women and 76 years for men—the growing number of Americans age 65 and older will face new challenges from chronic conditions such as arthritis, Alzheimer’s disease, cardiovascular disease and diabetes, which impact their health, productivity and independence. Those diseases not only impact the individuals living with them, but burden their families and cost the health care system billions of dollars.
Biopharmaceutical research companies are developing 435 medicines targeting 15 leading chronic conditions affecting seniors—Alzheimer’s and dementia, anemia, arthritis, benign prostatic hyperplasia, cataracts and glaucoma, chronic
kidney disease, chronic obstructive pulmonary disease (COPD), depression, diabetes, heart failure, hyperlipidemia,
hypertension, hypothyroidism and ischemic heart disease.
The document discusses the rationale and logistics for establishing a chronic kidney disease (CKD) clinic. It notes that CKD is a growing problem due to the rise of lifestyle diseases like diabetes and hypertension. A CKD clinic would take a multidisciplinary team approach to managing CKD patients and aim to slow disease progression, control comorbidities, and delay the need for renal replacement therapies. Studies show that CKD clinics that coordinate specialized care result in better health outcomes for patients than traditional nephrology care models.
Running head MEDICAL CARE PLANNING FOR PATIENTS WITH CHRONIC KIDN.docxjeanettehully
Running head: MEDICAL CARE PLANNING FOR PATIENTS WITH CHRONIC KIDNEY DISEASE
Medical care planning for patients with Chronic Kidney DiseaseNorys GilSouth University
Medical care planning for patients with Chronic Kidney Disease
Introduction
Chronic Kidney is a disorder that disturbs the correct working of the kidney, which is increasingly becoming a challenge to the health care sector. Just like any other chronic disease, CKD comes with the responsibility of ensuring that a patient gets maximum medical treatment facilities and attention as much as possible. “The definition and classification of chronic kidney disease (CKD) have evolved, but current international guidelines define this condition as decreased kidney function as shown by glomerular filtration rate (GFR) of less than 60 mL/min per 1·73 m2 or markers of kidney damage, or both, of at least three months duration, regardless of the underlying cause”, Morton & Masson, 2017.
Morbidity and comorbidity of chronic Kidney disease
Weak/low results are closely associated with CKD; this is because of the burdens that are so high when it comes to comorbidity. Many pieces of research have indicated that CKD relates to diabetes and hypertension conditions. Intense conditions of chronic kidney disease also lead to heart complications. There is little information on the mental difficulties that come with CKD.
“Chronic kidney disease (CKD) can be associated with adverse clinical outcomes, poor quality of life, and high health-care costs; clinicians need to understand that these observations result from a high burden of comorbidity among CKD patients”, (Manns &Hemmelgarn 2010). Key morbidities of CKD, therefore, include pulmonary complications, diabetes, hypertension, and atrial fibrillation. CKD, to a very high degree, leads to characteristics such as myocardial infarction, dementia, hypothyroidism, depression, and stroke. All comorbidities remain classified as concordant others that closely relate with CKD but ranked as discordant include; asthma, constipation, lymphoma dementia, etc.
Impacts of chronic kidney disease
Various medical reports by the health care agencies and organizations, including the World Health Organization show that CKD is a growing complication that has become a big concern of the public health care sector not just in the United States but around the globe. An estimation of over 26 million people is affected by CKD in the country. Annual reports have shown that this number is likely to increase if serious investments are in the health care sector. Hypertension and diabetes are proven, leading causes of kidney complications. To an individual, CKD can lead to other primary complications such as nephropathy, lupus, and continuity of kidney failure. The country invests billions of money annually, something that is becoming hard to sustain because of the annual increase in population and the number of those affected by CKD.
As of 2006, over $23 billion was spent on C ...
This document provides information about the 3rd International Conference on Diabetes, Endocrinology and Obesity to be held virtually on March 20-21, 2023. The conference will include keynote presentations, distinguished speaker talks, concurrent sessions on various topics related to diabetes, endocrinology and obesity. Some of the session topics include diabetes mellitus types 1 and 2, gestational diabetes, thyroid disorders, cardiovascular risk, and emerging focuses in diabetes research. The scientific program outlines the schedule of presentations for the two day event.
The document discusses challenges with the current state of medical care in the United States, including overemphasis on subspecialization, high costs due to unnecessary diagnostic testing and interventions, poor quality of care according to several studies, geographic variation in care, and influence of the pharmaceutical industry. It notes upcoming shortages of primary care physicians and specialists. Opportunities for collaboration between institutions via educational programs are highlighted.
The document discusses the benefits of a multi-disciplinary diabetes centre model of care compared to other models. A diabetes centre provides comprehensive care through a team that includes doctors, nurses, dietitians, podiatrists, and other specialists. This coordinated model results in better screening and management of complications, standardized processes, shorter wait times, and more flexibility compared to a clinic-based model with rotating doctors. The author argues the centre model can better serve the complex needs of people with diabetes.
What are the differences in publishing diabetes epidemiological manuscripts.pdfPubrica
The scientific and medical research papers produced by Pubrica's team of researchers and writers may be an invaluable tool for authors and practitioners.
Our aim is to alleviate human suffering related to diabetes and its complications among those least able to withstand the burden of the disease. From 2002 to March 2017, the World Diabetes Foundation provided USD 130 million in funding to 511 projects in 115 countries. For every dollar spent, the Foundation raises approximately 2 dollars in cash or as in-kind donations from other sources. The total value of the WDF project portfolio reached USD 377 million, excluding WDF’s own advocacy and strategic platforms.
This systematic review examined the effectiveness of disease management and case management for people with diabetes. The review found:
1) Disease management was effective in improving glycemic control, screening for diabetic complications, and monitoring of lipid levels.
2) Case management was effective in improving both glycemic control and provider monitoring of glycemic control, particularly in managed care settings in the U.S. for adults with type 2 diabetes.
3) Case management delivered with disease management or additional interventions was also effective.
There is a high burden of poor cardiovascular-kidney-metabolic health in the population, which affects nearly all organ systems and has a powerful impact on cardiovascular disease incidence. More guidance is needed on definitions, staging, prediction strategies, and algorithms for prevention and treatment of cardiovascular-kidney-metabolic syndrome to optimize health. Therapies now exist that can beneficially impact metabolic risk factors, kidney function and cardiovascular outcomes.
This document provides standards of care for diabetes in 2022 as published by the American Diabetes Association. It contains guidelines on topics such as classification and diagnosis of diabetes, prevention and management of comorbidities, glycemic targets, technology, pharmacologic treatment, and management of diabetes in special populations and contexts. The document is intended to provide evidence-based recommendations for health care professionals on diabetes care, management, and treatment.
The Nephrologists Congress 2020 conference will be held June 22-23, 2020 in Abu Dhabi, UAE. The conference will focus on advances in nephrology and hypertension through keynote presentations, workshops, and oral presentations from leading researchers. Topics will include nephrology therapeutics, urology, clinical nephrology, pediatric nephrology, hereditary kidney disorders, geriatric nephrology, nephrectomy, kidney transplantation, diabetes and hypertension, renal transplantation and immunology, kidney diseases, chronic and end stage renal diseases, and onconephrology. Attendees will include nephrologists, scientists, doctors, nurses,
This document is the 2022 Standards of Medical Care in Diabetes published by the American Diabetes Association (ADA). It provides evidence-based clinical practice recommendations to health care providers for the treatment and management of diabetes. The ADA publishes the Standards annually to ensure clinicians have the most up-to-date guidelines. The recommendations aim to improve diabetes outcomes and are not intended to replace clinical judgment tailored to individual patient circumstances.
Key Issues to Tackle to Build a Brighter Future for PCD Patients and CaregiversPCD Foundation
Identifies key challenges to overcome that will help people with primary ciliary dyskinesia (PCD) and other ciliopathies get the resources needed to improve the understanding of the disease, raise awareness about it, provide adequate and accessible treatments for it, improve diagnosis worldwide and ultimately greatly enhance the quality of life (and life span) of those affected by PCD.
A Guide to a Winning Interview June 2024Bruce Bennett
This webinar is an in-depth review of the interview process. Preparation is a key element to acing an interview. Learn the best approaches from the initial phone screen to the face-to-face meeting with the hiring manager. You will hear great answers to several standard questions, including the dreaded “Tell Me About Yourself”.
In the intricate tapestry of life, connections serve as the vibrant threads that weave together opportunities, experiences, and growth. Whether in personal or professional spheres, the ability to forge meaningful connections opens doors to a multitude of possibilities, propelling individuals toward success and fulfillment.
Eirini is an HR professional with strong passion for technology and semiconductors industry in particular. She started her career as a software recruiter in 2012, and developed an interest for business development, talent enablement and innovation which later got her setting up the concept of Software Community Management in ASML, and to Developer Relations today. She holds a bachelor degree in Lifelong Learning and an MBA specialised in Strategic Human Resources Management. She is a world citizen, having grown up in Greece, she studied and kickstarted her career in The Netherlands and can currently be found in Santa Clara, CA.
Learnings from Successful Jobs SearchersBruce Bennett
Are you interested to know what actions help in a job search? This webinar is the summary of several individuals who discussed their job search journey for others to follow. You will learn there are common actions that helped them succeed in their quest for gainful employment.
LinkedIn for Your Job Search June 17, 2024Bruce Bennett
This webinar helps you understand and navigate your way through LinkedIn. Topics covered include learning the many elements of your profile, populating your work experience history, and understanding why a profile is more than just a resume. You will be able to identify the different features available on LinkedIn and where to focus your attention. We will teach how to create a job search agent on LinkedIn and explore job applications on LinkedIn.
Khushi Saini, An Intern from The Sparks Foundationkhushisaini0924
This is my first task as an Talent Acquisition(Human resources) Intern in The Sparks Foundation on Recruitment, article and posts.
I invitr everyone to look into my work and provide me a quick feedback.
2. 2 |
Scientific Organizing Committee - International Committee for Insulin Resistance - ICIR
Yehuda Handelsman, MD Chair
Tarzana, CA
Richard N. Bergman, PhD
Los Angeles, CA
Zachary T. Bloomgarden, MD
New York, NY
Matthew J. Budoff, MD
Los Angeles, CA
Sonia Caprio, MD
New Haven, CT
Robert J. Chilton, DO
San Antonio, TX
Kenneth Cusi, MD
Gainesville, FL
Jaime A. Davidson, MD
Dallas, TX
Ralph A. DeFronzo, MD
San Antonio, TX
Daniel Einhorn, MD
La Jolla, CA
Vivian A. Fonseca, MD
New Orleans, LA
W. Timothy Garvey, MD
Birmingham, AL
Peter J. Grant, MD
Leeds, United Kingdom
Jennifer Green, MD
Durham, North Carolina
George Grunberger, MD
Bloomfield Hills, MI
Chris K. Guerin, MD
Oceanside, CA
Paul S. Jellinger, MD
Hollywood, FL
Samuel Klein, MD
St. Louis, MO
Mikhail N. Kosiborod, MD
Kansas City, MO
Ronald M. Krauss, MD
Berkeley, CA
Norman Lepor, MD
Los Angeles, CA
Derek LeRoith, MD, PhD
New York, NY
Philip Levy, MD
Phoenix, AZ
Christos Mantzoros, MD, PhD
Boston, MA
Nikolaus Marx, MD
Aachen, Germany
Tracey L. McLaughlin, MD
Stanford, CA
Christian W. Mende, MD
La Jolla, CA
Jorge Plutzky, MD
Boston, MA
Richard Pratley, MD
Orlando, FL
Arun J. Sanyal, MD
Richmond, VA
Philipp E. Scherer, PhD
Dallas, TX
Alan R. Sinaiko, MD
Minneapolis, MN
Welcome.
It is my pleasure to invite you to the 19th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular
Disease (WCIRDC): Exploring New Frontiers in Metabolism—Tomorrow’s Clinical Science Today.
We are excited to announce that the 19th Annual WCIRDC returns live in person to the Hilton Universal City, Los Angeles.
Based on last year’s incredible success we continue to offer virtual participation- Live Online and On-Demand for 3
months, to accommodate our attendees from across the globe.
Since its inception, the congress has become the premier global meeting dedicated to metabolism- obesity, diabetes,
lipids, HTN, CKD, CVD, HF, and NAFLD. This is the only conference of its size that incorporates both clinical and basic
science. It offers an exclusive opportunity for professionals, researchers, and other clinicians to collaborate on emerging
scientific and management strategies. The WCIRDC faculty consists of distinguished global experts who link research to
clinical practice in a bench-to-bedside-to-bench approach that is unique to this state-of-the-art program.
During the 19th WCIRDC, we will honor Drs. Christos Mantzoros and Samuel Klein, the recipients of the 2020 and 2021
Gerald Reaven Distinguished Leader in Insulin Resistance Award. This year’s conference will cover a wide range of topics
including the most up-to-date CV outcome trials, research in - and management recommendations for- Obesity, Diabetes
insulin resistance, COVID-19, dyslipidemia, NAFLD & NASH, ASCVD, heart failure, CKD, CardioRenalMetabolism in youth,
hormones and atherosclerosis and much more.
Highlights of the conference will be: a special session- first time ever: Multispecialty – Management of Diabetes,
Cardiorenal & Metabolic Diseases – Practice Recommendations 2022; Diabetes – Past, Present & Future; CKD, HF and
ASCVD in patients with & without Diabetes; a Joint session with the Journal Metabolism; A Glimpse in the Future –
What’s in the Pipeline? Has the Beta Cell Been Forgotten?
Live in-person attendees will be able to participate in clinical workshops, meet the expert sessions and have an
opportunity to personally interact and meet, in an intimate setting, the world’s top professionals, experts, and most
esteemed leaders in their respective fields.
The 19th WCIRDC congress will feature a robust Poster Hall, Oral Abstract Presentations, an attractive Exhibit Hall, and
Industry Supported non-CME programs that will feature important new scientific concepts with some the world’s best-
known educators of their fields.
I look forward to you joining this exciting conference on December 2–4, 2021, in Los Angeles.
Best regards,
Yehuda Handelsman, MD
Chair & Program Director
Bart Staels, PhD
Lille, France
Pam R. Taub, MD
San Diego, CA
Muthiah Vaduganathan,
MD, MPH
Boston, MA
Matthew R. Weir, MD
Baltimore, MD
Paul Zimmet, AO, PhD
Melbourne, Australia
3. | 3
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease
(WCIRDC), now in its 19th year, is a unique and exciting multidisciplinary CME
conference. The Congress has become the premier global meeting dedicated to
diabetes, obesity, lipids, cardiovascular-kidney and liver disease linking basic research
to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism —
Tomorrow’s Clinical Science Today.
WCIRDC 2021 will return to Live in Person meeting at the Hilton Universal City Hotel
in Los Angeles, on December 2-4, 2021. The conference will also have a virtual
component- Streaming Live online followed by 90 days On Demand.
In this CME meeting participants can earn up to 24 CME & ABIM-MOC credits.
WCIRDC is the only meeting of its size combining basic and clinical science. For nearly
two decades it has brought researchers, physicians, clinicians, and other healthcare
professionals together for a distinctive international program that bridges the latest
developments from bench-to-bedside- to-bench. “I heard it first at the Congress” is a
frequent remark from the audience. WCIRDC offers attendees a unique experience to
interact with the distinguished global faculty. In an intimate setting, for a collaborative
experience that explores the newest understanding of metabolic diseases and the
development of future therapeutic modalities.
Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between
insulin resistance (IR), diabetes, obesity, CVD, the Congress’ focus has expanded
to cover the kidney, liver, brain, bone, cancer, and more. The congress addresses
dyslipidemia, atherosclerosis, hypertension, hypercoagulation, inflammation, and
energy metabolism. It provides the newest clinical updates on pharmaceutical
interventions such as GLP1ra, SGLT2i’s, PCSK9i’s, MRA and EPA to name a few. The
goal is to understand the state-of-the-art pathophysiology, new medical interventions,
and to develop appropriate comprehensive clinical management strategies.
To make basic and clinical research topics relevant to clinical medicine, following each
session there will be live Q&A and a discussion on implications to clinical practice. To
promote more interaction with faculty and provide further insights, each day will end
with one hour of live panel, providing summary of the day, commentary, and open
for Q&A.
The Congress attracts state-of-the-art abstracts attracting, young up-and-coming
researchers as well as recognized leaders from around the globe. The abstracts will be
published in Metabolism, a peer-reviewed journal and also available for 90 days on
demand.
The congress is featured by many media outlets with proceedings featured in global
medical news venues such as Healio, Medscape, Endocrinology & Cardiology Today,
Clinical Endocrinology News, Practical Cardiology, HCP Live, and more, while articles
are being published in peer-reviewed journals like Journal of Diabetes, Endocrine
Practice, Metabolism, Diabetes & Vascular Disease Research, Diabetes and its
complications and others.
PROGRAM DESCRIPTION
The program is designed to evaluate the clinical and basic science aspects of diabetes,
obesity, HTN, dyslipidemia, CVD, HF, CKD, and related cardiometabolic conditions;
focusing on basic science such as insulin resistance, fat cells, inflammation, and on
clinical practice; understanding the comprehensive management cardiorenalmetabolic
conditions.
Upon completion of this meeting, participants should be able to:
• Discuss COVID-19 in diabetes and Obesity.
• Describe the relationship between diabetes, obesity, and heart failure
• Discuss T1D obesity and CVD
• Discuss the role of the beta cells in diabetes
• Discuss the role of fat cells in the development of cardiometabolic conditions
• Explain the roles of diabetes in the development of micro & macrovascular
conditions: kidney disease, retinopathy, neuropathy, CVD, and strokes
• Provide the traditional comprehensive management of diabetes, addressing
obesity, hypertension, dyslipidemia, and hyperglycemia.
• Highlight the paradigm shift in management focusing on preventing the next
evet of ASCVD, HF and CKD
• Discuss the role of GLP1ra in the management of diabetes, obesity, and
prevention of ASCVD.
• Evaluate SGLT2 inhibitors role in reducing cardiovascular morbidity & mortality
in patients with and without T2D and at risk for or established CVD
• Address SGLT2i role in managing patients with CKD and HFrEF & HFpEF
• Explain the role of PCSK9 inhibitors in preventing CV morbidity in people with
established ASCVD
• Discuss fatty liver disease and its relationship to diabetes and CVD
• Evaluate the impact on the clinical practice of lipid CV outcome trials, including
IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
• Examine the impact of Coagulation in diabetes in prevention of CVD and CVA
• Technology in monitoring and reducing DM & ASCVD
• Address the multispecialty practice recommendations to managing patients with
cardiorenalmetabolic diseases
PROGRAM OBJECTIVES
This educational initiative is designed for endocrinologists, cardiologists, nephrologists, family physicians, internists, diabetologists, gastroenterologists, pediatricians, OB/
GYN, researchers, nurse practitioners, physician assistants, dieticians, diabetes educators, and other healthcare professionals interested in the pathophysiology, prevention, and
treatment of diabetes, obesity, CVD, CKD, HF, and associated conditions, as well as the effect of these conditions on health and society.
TARGET AUDIENCE
4. 4 |
PROGRAM 2021 THURSDAY, DECEMBER 2, 2021
7:00 am Pre-Registration
7:00 am – 8:00 am EXHIBIT HALL OPEN
8:00 am – 8:15 am Welcome & Introduction | Pre-CME Questions
SESSION 1 Has the Beta Cell Been Forgotten?
Chair: Ralph DeFronzo, MD
8:15 am Muhammad Abdul-Ghani, MD, PhD
8:30 am John Leahy, MD
8:45 am Rohit Kulkarni, MD, PhD
9:00 am Steven Kahn, MD
9:15 am
Beta Cell Failure and T2DM: Human Studies
Role of Glucotoxicity and Lipotoxicity in Beta Cell Failure
Role of mRNA Modifications in Regulating Islet Cell Biology
Gene Mutations Play a Dominant Role in Beta Cell Failure in T2DM
Antidiabetic Agents and Prevention of Beta Cell Failure: Fact & Fiction Ralph DeFronzo, MD
9:30 am – 9:50 am Panel Discussion and Q&A
SESSION 2 COVID-19 in CardioRenalMetabolism
Chairs: Chris Guerin, MD • Christian W. Mende, MD
9:50 am Cardiovascular Complications of COVID: Challenges and Insights Michael E. Farkouh, MD
10:05 am Obesity and COVID-19 – What is the Link? Tracey L. McLaughlin, MD
10:20 am Managing Inflammation in COVID-19 Patients Focus on Colchicine Norman E. Lepor, MD
10:35 am – 10:50 am Panel Discussion and Q&A
10:50 – 11:20 am REFRESHMENT BREAK
11:20 am – 12:10 pm Concurrent Sessions MEET THE EXPERTS (In-Person Only)
Daniel Einhorn, MD Cortisol & Metabolism Sierra C/D
Ralph DeFronzo, MD Everything Insulin Resistance Club Room
Matthew Budoff, MD ASCVD Diagnosis Management Hiro Room
Yehuda Handelsman, MD DM & the Heart A Paradigm Shift Salon 6AB
12:15 pm – 1:15 pm LUNCH BREAK
12:20 pm - 1:05 pm Lunch Session Non-CME Product Theater Hall
Jardiance® (empagliflozin) tablets: A Review of the Latest Data Norman Lepor, MD
Supported by: Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA, LLC
SESSION 3 The Liver: NAFLD & NASH
Chairs: Jennifer Green, MD • Daniel Einhorn, MD
1:15 pm Diagnosis and Treatment of Patients with NAFLD/NASH – The Future Mazen Noureddin, MD
1:35 pm The Liver and the Heart Laurence Sperling, MD
1:55 pm – 2:10 pm Panel Discussion and Q&A
5. | 5
THURSDAY, DECEMBER 2, 2021 (cont.)
SESSION 4 CardioRenalMetabolism in Youth
Chairs: Alan R. Sinaiko, MD • Sonia Caprio, MD
2:10 pm Value of Early Lipid-Lowering Interventions to Prevent Later Life Cardiovascular Disease Andrew Moran, MD, MPH
2:25 pm Co-existence of Prediabetes and Non-Alcoholic Fatty Liver Disease in Pediatric Obesity Sonia Caprio, MD
2:40 pm Long-term complications in youth-onset type 2 diabetes: the TODAY study Phil Zeitler, MD, PhD
2:55 pm – 3:15 pm Panel Discussion and Q&A
3:15 pm – 3:45 pm REFRESHMENT BREAK
SESSION 5 Diabetes – Special Populations
Chairs: Zachary Bloomgarden, MD • Tracey L. McLaughlin, MD
3:45 pm LADA: Epidemiology similarities & differences from T2D/T1D – Impact on Comorbidities Richard E. Pratley, MD
4:05 pm C-peptide Levels and CVD Outcomes in the VADT Peter Reaven, MD
4:25 pm – 4:35 pm Panel Discussion and Q&A
SESSION 6 Dyslipidemia & ASCVD
Chairs: Paul S. Jellinger, MD • Matthew J. Budoff, MD
4:35 pm Beyond LDL-C: The Role of Dyslipidemia in ASCVD Ron M. Krauss, MD
4:55 pm Novel Agents and Combination Therapy in Management of Dyslipidemia Erin D. Michos, MD
5:15 pm – 5:30 pm Panel Discussion and Q&A
5:30 pm – 6:30 pm DAY 1 SUMMARY SESSION & POST-CME QUESTIONS
Sonia Caprio, MD • Ralph A. DeFronzo, MD • Jennifer Green, MD • Yehuda Handelsman, MD • Ronald M. Krauss, MD • Tracey L. McLaughlin, MD
6:30 pm – 7:30 pm WELCOME AND POSTER RECEPTION
7:30 pm – 8:30 pm Dinner Session Non-CME Product Theater Hall
An Overview of the FreeStyle Libre 2 System George Grunberger, MD
Supported by: Abbott
FRIDAY, DECEMBER 3, 2021
7:00 am – 8:00 am EXHIBIT HALL OPEN | Continental Breakfast
8:00 am – 8:10 am Pre-CME Questions
SESSION 7 Metabolism & WCIRDC – Joint Session
Chair: Michael A. Hill, PhD • Yehuda Handelsman, MD
8:10 am Insulin Action / Insulin Resistance / Diabetes and the Heart Dale Abel, MD, PhD
8:25 am Cardiovascular Actions and Therapeutic Potential of Novel Anti-Diabetic Agents Michael A. Hill, PhD
8:40 am Drug Development for Cardiometabolic Disorders - Focusing on the Patient Theodoros Kelesidis, MD, PhD
8:55 am – 9:10 am Panel Discussion and Q&A
6. FRIDAY, DECEMBER 3, 2021 (cont.)
SESSION 8 Hormones, Cytokine, & Insulin – Role in Morbidities
Chairs: Richard N. Bergman, PhD • Samuel Klein, MD
9:10 am Insulin Action and Insulin Resistance in the Kidney Gerald I. Shulman, MD, PhD
9:25 am FGF1 and Insulin Control Adipose Lipolysis by Convergent Pathways Ronald M. Evans, PhD
9:40 am Adiponectin & Leptin Roles in Cardiometabolic Control, Diabetes, Aging and Mortality Philipp E. Scherer, PhD
9:55 am – 10:15 am Panel Discussion and Q&A
10:15 am – 10:45 am REFRESHMENT BREAK
SESSION 9 Pumps, CGM, Risk Engine and Hypoglycemia
Chairs: Richard E. Pratley, MD • W. Timothy Garvey, MD
10:45 am BRAVO risk Engine – Simulating Trials and Evaluating Cost Vivian A. Fonseca, MD
11:00 am Clinical Guidelines 2021 - CGM and Insulin Pump Therapy George Grunberger, MD
11:15 am Hypoglycemia Contemporary approach to management Guillermo Umpierrez, MD
11:30 am – 11:45 am Panel Discussion and Q&A
SESSION 10 A Glimpse in the Future - What's in the Pipeline? (Non-CME)
Chairs: Ralph DeFronzo, MD • Tracey L. McLaughlin, MD
11:45 am Zealand David Kendall, MD
12:00 pm Boehringer Ingelheim Mohamed Eid, MD, MPH, MHA
12:15 pm Corcept Joe Belanoff, MD
12:30 pm Regeneron Sergio Fazio, MD, PhD
12:45 pm – 1:00 pm Panel Discussion and Q&A
1:00 pm – 2:00 pm LUNCH BREAK
1:10 pm – 1:55 pm Lunch Session Non-CME Product Theater Hall
Primary Hypercortisolism: What are We Missing and Why Does it Matter? Daniel Einhorn, MD
Supported by: Corcept Therapeutics
SESSION 11 DCRM Multispecialty Practice Recommendations for the Management of
Diabetes, Cardiorenal, and Metabolic Diseases
Chair: Yehuda Handelsman, MD
2:00 pm Matthew Budoff, MD • Daniel Einhorn, MD • Vivian Fonseca, MD • Jennifer Green, MD •
George Grunberger, MD • Christian Mende, MD • Erin D. Michos, MD
3:00 pm – 3:30 pm Panel Discussion and Q&A
3:30 pm – 4:00 pm REFRESHMENT BREAK
SESSION 12 The Heart, Metabolism and CVOT
Chairs: Peter J. Grant, MD • Norman E. Lepor, MD
4:00 pm Aortic Stenosis and Metabolic Diseases Robert J. Chilton, DO
4:15 pm Testosterone Treatment Impact on Atherosclerosis in Men Matthew J. Budoff, MD
4:30 pm Impact of Hormones on Cardiometabolic Health Pam R. Taub, MD
4:45 pm Update on CVOTs Mikhail N. Kosiborod, MD
5:10 pm – 5:30 pm Panel Discussion and Q&A
7. | 7
FRIDAY, DECEMBER 3, 2021 (cont.)
5:30 pm – 6:30 pm DAY 2 SUMMARY SESSION & POST-CME QUESTIONS
Ralph DeFronzo, MD • Yehuda Handelsman, MD • Samuel Klein, MD
Mikhail N. Kosiborod, MD • Norman E. Lepor, MD • Richard E. Pratley, MD
6:30 pm – 7:30 pm Dinner Session Non-CME Product Theater Hall
Add on Efficacy. Oral, Nonstatin Therapies for Lowering LDL-C Norman Lepor, MD
Supported by: Esperion Therapeutics
7:30 pm – 9:00 pm ABSTRACT ORAL PRESENTATION Sierra C/D Cheese & Wine
Zachary Bloomgarden, MD, Chair
Abstract Committee: Daniel Einhorn, MD • George Grunberger, MD • Philip Levy, MD
Abstracts are published in Metabolism Editor-in-Chief: Christos S. Mantzoros, MD, PhD
SATURDAY, DECEMBER 4, 2021
7:00 am – 8:00 am Continental Breakfast
7:00 am – 7:45 am Morning Session Non-CME Product Theater Hall
Clinical Utility of Glycated Albumin & Validation Studies as an
Intermediate Glycemic Control Marker Cyrus Desouza, MBBS
Supported by: Asahi Kasei Pharma Corporation
8:00 am – 8:05 am Abstract Oral Winner Presentation
8:05 am – 8:15 am Pre-CME Questions
SESSION 13 Diabetes – Past, Present & Future
Chairs: George Grunberger, MD • Vivian A. Fonseca, MD
8:15 am Insulin - 100 years of Progress Jay S. Skyler, MD
8:30 am The Importance of Long Term Management of Hyperglycemia Peter J. Grant, MD
8:45 am Early Combination Therapy in DM - Impact on Comorbidities Jennifer Green, MD
9:00 am Reversing Type 2 Diabetes from Day One Julio Rosenstock, MD
9:15 am – 9:35 am Panel Discussion and Q&A
SESSION 14 Obesity 2021 – A Paradigm Shift
Chairs: Ronald M. Krauss, MD • Matthew R. Weir, MD
9:35 am A New Era in Obesity Medicine: Treat-to-Target W. Timothy Garvey, MD
9:50 am What’s the Best Weight Loss Diet? Donna H. Ryan, MD
10:05 am Key Concepts in Treating Obesity as a Disease: A Focus on Pharmacological Interventions Ania Jastreboff, MD, PhD
10:20 am -10:35 am REFRESHMENT BREAK
8. 8 |
SATURDAY, DECEMBER 4, 2021(cont.)
GERALD REAVEN DISTINGUISHED LEADER IN INSULIN RESISTANCE – 2021 AWARD
10:35 am 2021 Award Presentation “Gerald Reaven Distinguished Leader in Insulin Resistance”
10:40 am Why Does Obesity Cause Type 2 Diabetes Samuel Klein, MD
11:10 am – 11:30 am Session 14 Panel Discussion and Q&A
11:30 am – 12:30 pm LUNCH BREAK
11:40 am – 12:25 pm Lunch Session Non-CME Product Theater Hall
The Role of the Gut in Type 2 Diabetes: Going Beyond Incretins
Supported by: Fractyl Health
Geltrude Mingrone, MD, PhD Randy Seeley, PhD
SESSION 15 Glucose Metabolism and Diabetes
Chairs: Philipp E. Scherer, PhD • Richard N. Bergman, PhD
12:30 pm Insulin Resistance Impact on Insulin Clearance and Metabolic Demand Effect on Glucose Tolerance Ralph DeFronzo, MD
12:45 pm Statin Associated with Increased Insulin Resistance & Diabetes Joshua W. Knowles, MD
1:00 pm – 1:10 pm Panel Discussion and Q&A
SESSION 16 CKD, HF and ASCVD in Diabetes & Without
Chairs: Pam R. Taub, MD • Peter J. Grant, MD
1:10 pm The Role of (Micro) Albuminuria in Predicting HF, ASCVD and CKD Richard E. Pratley, MD
1:25 pm The Prevention of ASCVD in Patients with Diabetes Ildiko Lingvay, MD
1:40 pm Update in HF Management – How Should/Would the Guidelines Look? Mikhail N. Kosiborod, MD
1:55 pm – 2:10 pm REFRESHMENT BREAK
2:10 pm Heart Failure today: A new epidemic or a co-morbidity Mark Kearney, MD
2:25 pm The Contemporary Approach to MRA, Aldosterone in the Kidney and the Heart Christian W. Mende, MD
2:40 pm Treatment of Diabetic Nephropathy: what does the future hold? Robert D. Toto, MD
2:55 pm – 3:15 pm Panel Discussion and Q&A
3:15 pm – 4:10 pm DAY 3 SUMMARY SESSION & POST-CME QUESTIONS
Richard N. Bergman, PhD • W. Timothy Garvey, MD • Peter J. Grant, MD
George Grunberger, MD • Yehuda Handelsman, MD • Pam R. Taub, MD
4:15 pm – 5:00 pm Concurrent Sessions CLINICAL WORKSHOPS (In-Person Only)
Management of DM Sierra Ballroom C/D Yehuda Handelsman, MD
All You Wanted to Know about CGM Sierra Ballroom B George Grunberger, MD
Lipids Club Room Paul Jellinger, MD • Paul Rosenblit, MD
9. | 9
FACULTY 2021
Yehuda Handelsman, MD, FACP,
FNLA, FASPC, MACE
Medical Director & Principal Investigator
The Metabolic Institute of America
Chair & Program Director
World Congress on Insulin Resistance,
Diabetes & Cardiovascular Disease (WCIRDC)
/ Heart in Diabetes (HID)
Chair & Founder
International Committee for Insulin Resistance
Tarzana, California
Muhammad Abdul-Ghani, MD,
PhD
Professor of Medicine, Division of Diabetes
University of Texas Health Science
Center at San Antonio
San Antonio, TX
Dale Abel, MD, PhD
Professor & Head
Internal Medicine
University of Iowa Carver College of Medicine
Iowa City, Iowa
Joseph K. Belanoff, MD
Chief Executive Officer, President and Director
Corcept Therapeutics
Richard N. Bergman, PhD
Alfred Jay Firestein Chair in Diabetes
Research Professor
Department of Biomedical Sciences
Cedars-Sinai Director
Sports Spectacular Diabetes and Obesity
Wellness and Research Center (SSDOWRC)
Professor-in-Residence,
Department of Medicine, UCLA
Los Angeles, California
Zachary T. Bloomgarden, MD,
MACE
Clinical Professor Department of Medicine
Icahn School of Medicine at Mount Sinai
Editor, The Journal of Diabetes
New York, New York
Matthew J. Budoff, MD
FACC, FAHA
Professor of Medicine
David Geffen School of Medicine at UCLA
Endowed Chair of Preventive Cardiology
Program Director, Director of Cardiac CT
Lundquist Institute
Harbor-UCLA Medical Center
Division of Cardiology
Los Angeles, California
Sonia Caprio, MD
Professor of Pediatric Endocrinology
Yale University School of Medicine
New Haven, Connecticut
Robert J. Chilton, DO, FACP,
FACC, FAHA, MACOI, FASCAI
Professor of Medicine
Department of Medicine
Division of Cardiology
The University of Texas Health Science Center
San Antonio, Texas
Ralph A. DeFronzo, MD
Professor of Medicine Chief
Diabetes Division
University of Texas Health Science
Center at San Antonio
San Antonio, Texas
Mohamed A. Eid, MD
MPH, MHA
Head of Clinical Development & Medical Affairs
Cardio-Renal-Metabolism &
Respiratory Medicine
Boehringer Ingelheim Pharmaceuticals Inc.
Ridgefield, Connecticut
Daniel Einhorn, MD, FACP, FACE
Chief, Diabetes and Endocrine Associates
Medical Director
Scripps Whittier Diabetes Institute
Clinical Professor, UCSD School of Medicine
La Jolla, California
Ronald M. Evans, PhD
Professor and Director
Gene Expression Laboratory
March of Dimes Chair in Molecular and
Developmental Biology
La Jolla, California
Michael E. Farkouh, MD, MSc,
FRCPC, FACC, FAHA
Peter Munk Chair in Multinational Clinical Trials
Director, Heart & Stroke Richard Lewar
Centre of Excellence
Vice-Chair Research & Professor of Medicine
Department of Medicine
University of Toronto
Toronto, Ontario, Canada
Sergio Fazio, MD, PhD
Chair, Scientific Council - CV/Metabolic
Regeneron Pharmaceuticals
New York, New York
Vivian A. Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana
W. Timothy Garvey, MD
Butterworth Professor
Department of Nutrition Sciences
University of Alabama at Birmingham
Director, UAB Diabetes Research Center
Birmingham, Alabama
Peter J. Grant, MD
FRCP, FMedSci
Professor of Medicine
Honorary Consultant Physician
University of Leeds
Leeds Teaching Hospitals NHS Trust
Division of Cardiovascular & Diabetes Research
LIGHT Laboratories
Leeds, United Kingdom
Jennifer Green, MD
Professor of Medicine
Duke University Medical Center
Division of Endocrinology
Duke Clinical Research Institute
Durham, North Carolina
10. 10 |
George Grunberger, MD
FACP, MACE
Chairman, Grunberger Diabetes Institute
Clinical Professor, Internal Medicine and
Molecular Medicine & Genetics
Wayne State University School of Medicine
Professor, Internal Medicine
Oakland University William Beaumont
School of Medicine
Visiting Professor, Internal Medicine
First Faculty of Medicine
Charles University, Prague, Czech Republic
Bloomfield Hills, Michigan
Chris K. Guerin, MD
Chief, Division of Endocrinology and
Metabolism
Tri-City Medical Center at Oceanside, California
Founder-Advanced Metabolic Care and
Research
Voluntary Assistant Clinical Professor
University of California at San Diego
Chair Past President’s Committee for CACE
and Board of Directors
San Diego, California
Michael A. Hill, PhD
Interim Director, Dalton Cardiovascular
Research Center
Professor, Department of Medical
Pharmacology and Physiology,
School of Medicine
University of Missouri Columbia, Missouri
Ania Jastreboff, MD, PhD
Associate Professor
Director, Weight Management &
Obesity Prevention
Medical Director, Yale Stress Center
New Haven, Connecticut
Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
Voluntary Faculty University of Miami, Miller
School of Medicine
The Center for Diabetes & Endocrine Care
Past President, AACE & ACE
Hollywood, Florida
Steven E. Kahn, MD
Division of Metabolism
Endocrinology and Nutrition
Department of Medicine
VA Puget Sound Health Care System
University of Washington
Seattle, Washington
Mark Kearney, MD
MBChB, MRCP
British Heart Foundation Professor of
Cardiovascular and Diabetes Research
Leeds Institute of Cardiovascular
& Metabolic Medicine
Dean of the School of Medicine
University of Leeds
Leeds, United Kingdom
Theodoros Kelesidis, MD, PhD
Associate Professor
Department of Medicine
Division of Infectious Diseases
David Geffen School of Medicine at UCLA
Encino, California
David Kendall, MD
Sr. Global Medical Advisor
Zealand Pharma
Westlake Village, California
Samuel Klein, MD
Director, Center for Human Nutrition
Chief Scientific Officer, Sansum Diabetes
Research Institute
Washington University School of Medicine
Saint Louis, Missouri
Joshua W. Knowles, MD, PhD
Assistant Professor, Cardiovascular Medicine
Stanford University
Attending Physician, Stanford Center for
Inherited Cardiovascular Disease
Director, Familial
Hypercholesterolemia (FH) Clinic
Program Director, Stanford Cardiovascular
Medicine Fellowship Program
Co-director, Stanford Translational
Investigator Program
Stanford, California
Mikhail N. Kosiborod MD
FACC, FAHA
Professor of Medicine
Saint Luke’s Mid America Heart Institute
University of Missouri-Kansas City
School of Medicine
Kansas City, Missouri
Ronald M. Krauss, MD
Senior Scientist and Director
Atherosclerosis Research
Children’s Hospital Oakland Research Institute
Adjunct Professor
Department of Medicine, UCSF
Adjunct Professor
Department of Nutritional Sciences
University of California, Berkeley
Berkeley, California
Rohit Kulkarni, MD, PhD
Islet Cell and Regenerative Biology
Co-Section Head and Senior Investigator
Joslin Diabetes Center, Department of Medicine
Brigham and Women’s Hospital
Harvard Stem Cell Institute
Harvard Medical School
Boston, Massachusetts
John Leahy, MD
Professor Emeritus, Department of Medicine
Division of Endocrinology
Diabetes and Metabolism
Colchester, Vermont
Norman E. Lepor, MD
FACC, FAHA, FSCAI
Clinical Professor of Medicine Geffen/UCLA
School of Medicine
Smidt Cedars-Sinai Heart Institute
Westside Medical Associates of Los Angeles
Los Angeles, California
Philip Levy, MD, MACE
Clinical Professor of Medicine
University of Arizona College of Medicine
Endocrinologist
Banner University Medical Group
Phoenix, Arizona
FACULTY 2021
11. | 11
Ildiko Lingvay, MD
MPH, MSCS
Professor of Medicine
Department of Internal Medicine
Division of Endocrinology and
Department of Population and Data Sciences
Medical Director
Office of Clinical Trial Management
University of Texas
Southwestern Medical Center
Dallas, Texas
Christos S. Mantzoros, MD
DSc, PhD h.c. mult.
Professor of Medicine
Harvard Medical School and
Boston University School of Medicine
Chief of Endocrinology
Diabetes and Metabolism
Boston VA Healthcare System
Director of Human Nutrition, Beth Israel
Deaconess Medical Center
Editor-in-Chief, Metabolism,
Clinical & Experimental
Boston, Massachusetts
Tracey L. McLaughlin, MD, MS
Professor of Medicine
Division of Endocrinology
Stanford University School of Medicine
Stanford, California
Christian W. Mende, MD
FACP, FACN, FASN, FASH
Clinical Professor of Medicine
University of California San Diego
La Jolla, California
Erin D. Michos, MD, MHS,
FAHA, FACC, FASE, FASPC
Associate Professor of Medicine (Cardiology)
and Epidemiology
Associate Director of Preventive Cardiology
Johns Hopkins University School of Medicine
Baltimore, Maryland
Andrew Moran, MD, MPH
Director, Global Hypertension Control
Resolve to Save Lives
Associate Professor of Medicine
Columbia University
New York, New York
Mazen Noureddin, MD
Director, Cedars-Sinai Fatty Liver Program
Los Angeles, California
Richard E. Pratley, MD
Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida
Peter Reaven, MD
Professor of Clinical Medicine
University of Arizona
Phoenix, Arizona
Paul D. Rosenbilt MD
PhD, FACE, FNLA
Clinical Professor, Medicine
Division of Endocrinology
Diabetes Metabolism
University of California, Irvine (UCI)
School of Medicine
Co-Director, Diabetes Outpatient Clinic
UCI Medical Center, Orange, CA
Director, & Site Principal Investigator
Diabetes / Lipid Management &
Research Center
Huntington Beach, California
Julio Rosenstock, MD
Director, Dallas Diabetes Research Center
Medical City Dallas
Clinical Professor of Medicine
University of Texas Southwestern
Medical Center
Dallas, Texas
Donna H. Ryan, MD
Professor Emerita
Pennington Biomedical Research Center
New Orleans, Louisiana
Philipp E. Scherer, PhD
Touchstone Diabetes Center
The University of Texas Southwestern
Medical Center
Dallas, Texas
Gerald I. Shulman, MD, PhD
George R. Cowgill Professor of Medicine
(Endocrinology)
Professor of Medicine and Cellular
& Molecular Physiology
Co-Director Yale Diabetes Research Center
Yale University School of Medicine
New Haven, Connecticut
Alan R. Sinaiko, MD
Professor, Department of Pediatrics
Division of Pediatric Nephrology
University of Minnesota Medical School
Minneapolis, Minnesota
Jay S. Skyler, MD, MACP
Professor of Medicine
Pediatrics and Psychology
Deputy Director, Diabetes Research Institute
University of Miami
Miami, Florida
Laurence Sperling, MD
FACC, FAHA, FACP, FASPC
Katz Professor in Preventive Cardiology
Founder, Emory Heart Disease Prevention
Professor of Global Health
Emory University
Atlanta, Georgia
FACULTY 2021
12. 12 |
19TH WCIRDC PROGRAM COMMITTEE
Yehuda Handelsman, MD, Chair • Richard N. Bergman, PhD • Zachary T. Bloomgarden, MD • Matthew J. Budoff, MD
Sonia Caprio, MD • Robert J. Chilton, DO • Kenneth Cusi, MD • Jaime Davidson, MD • Ralph A. DeFronzo, MD • Daniel Einhorn, MD
Vivian A. Fonseca, MD • W. Timothy Garvey, MD • Peter J. Grant, MD • Jennifer Green, MD • George Grunberger, MD
Chris K. Guerin, MD • Paul S. Jellinger, MD • Samuel Klein, MD • Mikhail N. Kosiborod, MD
Ronald M. Krauss, MD • Norman Lepor. MD • Derek LeRoith, MD, PhD • Philip Levy, MD • Christos Mantzoros, MD, DSc
Nikolaus Marx, MD • Tracey L. McLaughlin, MD • Christian W. Mende, MD • Jorge Plutzky, MD • Richard E. Pratley, MD
Arun J. Sanyal, MD • Philipp E. Scherer, PhD • Bart Staels, PhD • Pam R. Taub, MD • Muthiah Vaduganathan, MD, MPH
Matthew R. Weir, MD • Paul Zimmet, AO, PhD • Renee S. Asp, BS
ACCOMMODATIONS
The 19th Annual World Congress on Insulin Resistance, Diabetes & CVD (WCIRDC) will be held at the prestigious Hilton Universal City Hotel. The majestic
Hilton Hotel is situated on a high hill above the Los Angeles entertainment district, near Universal Studios Hollywood and City Walk. The hotel is located a
block from the main entrance of Universal Studios Hollywood, and is also a 3.5-mile drive to Pantages Theatre for Broadway shows. This 24-story hotel offers
upscale rooms with panoramic views of the Hollywood Hills and Universal Studios.
Hilton Universal City Hotel 555 Universal Hollywood Drive Universal City, CA 91608
To reserve a room at our special rate of $216 a night for conference participants and their guests visit https://www.wcir.org/accommodations
Guests can also call In-House Reservations Dept. at 818-623-1434 from 8:30am-5pm PST Please reference the group name: WCIRDC
Pam R. Taub, MD, FACC, FASPC
Director of Step Family Foundation
Cardiovascular
Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System
Division of Cardiovascular Medicine
La Jolla, California
Robert D. Toto, MD
Professor of Internal Medicine
Associate Dean Translational Science
and Education
University of Texas Southwestern Medical
Center
Dallas, Texas
Guillermo Umpierrez, MD, CDE
Professor of Medicine
Division of Endocrinology, Metabolism, and
Lipids
Emory University
Atlanta, Georgia
Matthew R. Weir, MD
Professor and Chief
Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland
Phil Zeitler, MD, PhD
Medical Director, Children’s Hospital Colorado
Clinical & Translational Research Center,
Section Head, Endocrinology
Aurora, Colorado
FACULTY 2021
13. | 13
CME ACCREDITATION
For CME questions related to WCIRDC, please
contact our CME Coordinator Renee Asp at
renee@aspencmehelp.com. This activity
was planned and implemented in accordance
with the Essential Areas and Policies of the
Accreditation Council for Continuing Medical
Education through the joint providership of PESI
Inc. and the Metabolic Endocrine Education
Foundation (MEEF). PESI Inc. is accredited
by the ACCME to provide continuing medical
education for physicians.
AMA PRA DESIGNATION
STATEMENT
PESI Inc. has designated this Other (Live and
Internet Live ) activity for a maximum of 24
AMA PRA Category 1 Credit(s)
™. Physicians
should only claim credit commensurate with the
extent of their participation in the activity.
MOC POINTS WITH ABIM
Successful completion of this CME activity,
which includes participation in the evaluation
component, enables the participant to earn MOC
points of Medical Knowledge MOC points in the
American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program.
Total qualifying MOC points 24.
INTERNATIONAL CME
International Physicians are formally eligible
for AMA PRA Category 1 Credit™.
PHYSICIAN ASSISTANTS
AAPA accepts Category 1 credit from AOACCME,
Prescribed credit from AAFP, and AMA PRA
Category 1 Credit™ for the PRA from
organizations accredited by ACCME.
NURSES
For the purpose of re-certification, the American
Nurses Credentialing Center accepts AMA PRA
Category 1 Credit™ issued by organizations
accredited by the ACCME (Accreditation Council
for Continuing Medical Education) for attendance
at structured learning activities.
CA NURSES
Aspen CME Services is approved by
the California Board of Registered Nursing,
provider number CEP14739, designated
the 19th WCIRDC for a total of 24 contact
hours.
PHARMACISTS
For the purpose of re-certification, the American
Council of Pharmacy Education accepts AMA PRA
Category 1 Credit™ issued by organizations
accredited by the ACCME (Accreditation Council
for Continuing Medical Education) for attendance
at structured learning activities.
CDE
The National Certification Board for Diabetes
Educators recognizes courses sponsored
by PESI Inc. as approved ACCME provider.
Total qualifying continuing education hours 24.
REGISTERED DIETITIANS
For the purpose of re-certification, the
Commission on Dietetic Registration recognizes
courses accredited with AMA PRA Category 1
Credit™.
SATISFACTORY COMPLETION
FOR CREDITS
All attendees must have completed and
submitted an online course attendance/
evaluation immediately following onsite or
virtually live attendance. Each session claimed
for credit must be attended in its entirety.
Attendees will be able to print a certificate of
attendance following the submission of online
evaluation. Physician certificates of credit will
be emailed two to three weeks after the CME
activity.
ENDURING/ ON-DEMAND CME
ACTIVITY
This activity was planned and implemented
in accordance with the Essential Areas and
Policies of the Accreditation Council for
Continuing Medical Education through the joint
providership of PESI Inc. and the Metabolic
Endocrine Education Foundation (MEEF). PESI
Inc. is accredited by the ACCME to provide
continuing medical education for physicians.
AMA PRA DESIGNATION
STATEMENT
PESI Inc. has designated this Enduring activity
for a maximum of 24 AMA PRA Category
1 Credit(s)
™. Physicians should only claim
credit commensurate with the extent of their
participation in the activity.
Available online at www.wcirdc.com from
December 6, 2021 through March 4, 2022.
REGISTRATION INFORMATION
www.WCIR.ORG/registration
Email: info@tmioa.com | To register by phone: 818- 342 -1889
All 19th WCIRDC participants must be vaccinated in order to attend the live in person meeting.For further information please contact info@tmioa.com
Cancellation Policy: A full refund will be given if written notice of cancellation is received by September 6, 2021. A $75 cancellation fee will be
charged for cancellation between September 7, 2021 and November 2, 2021. After November 2, 2021 there will be NO REFUNDS - only registration
transfer credit will be offered. Cancellations must be submitted via e-mail to info@tmioa.com or by phone at 818-342-1889.
14. 14 |
FOR ADDITIONAL INFORMATION ON
Registration | Support | Exhibits
(818) 342-1889 | info@tmioa.com | wwww.WCIR.ORG
ASSOCIATED ORGANIZATIONS MEDIA PARTNERS
Premier Associated Organizations Premier Media Partners
Associated Organizations Media Partners
• California Chapter of the American College of Cardiology
(CAACC)
• Clinical Association of California Endocrinologists (CACE)
• Cardio Renal Society of America (CRSA)
• Metabolism (Elsevier)
• American Journal of Cardiology (Elsevier)
• American Journal of Managed Care (MJH Life Sciences)
• Endocrinology Network (MJH Life Sciences)
• HCPLive Network (MJH Life Sciences)
• Healio: Cardiology Today & Endocrine Today
• Practical Cardiology (MJH Life Sciences)
• The Lancet Diabetes & Endocrinology
• American Society of Endocrine Physician Assistants (ASEPA)
• Association of Diabetes Care & Education Specialists (ADCES)
• Endocrine Nurses Society (ENS)
• International Federation for the Surgery of Obesity and
Metabolic Disorders (IFSO)
• Israel Endocrine Society (IES)
• Italian Society of Endocrinology (SIE)
• Point of Care Network (POCN)
• World Obesity Federation
• Cardiovascular Endocrinology & Metabolism (Wolters Kluwer)
• ConferenceLocate.com
• Diabetes & Vascular Disease Research (Sage)
• Diabetes in Control
• Endocrine Web
• Frontiers in Clinical Diabetes and Healthcare
• Healthcare Tech Outlook
• Journal of Diabetes
• MEDtube
• Nutrients
• PharmaVoice
• Physician's Weekly
• Vessel Plus
15. | 15
THE INTERNATIONAL COMMITTEE FOR
INSULIN RESISTANCE GRATEFULLY ACKNOWLEDGES
UNRESTRICTED EDUCATIONAL GRANT
CORPORATE SUPPORT
EMERALD LEVEL
TOPAZ LEVEL
BAYER
ASTRAZENECA
PFIZER / MERCK ALLIANCE
ZEALAND PHARMA
NOVO NORDISK
AMARIN PHARMA
16. Metabolic Endocrine Education Foundation
18372 Clark St #212
Tarzana, CA 91356
For Additional Information on
SUPPORT · REGISTRATION ∙ ACCOMMODATIONS ∙ EXHIBITION
818.342.1889 | 818.342.1538 | info@tmioa.com
www.wcir.org